In the era of highly-active antiretroviral therapy, why are HIV-infected patients still admitted to hospital for an inaugural opportunistic infection?

HIV Medicine

Volumn 6, Issue 4, 2005, Pages 232-239

  Perbost, Isabelle ^a   Malafronte, B ^a   Pradier, C ^a   Santo, L D I ^a   Dunais, B ^a   Counillon, E ^c   Vinti, H ^a   Enel, P ^b   Fuzibet, J G ^a   Cassuto, J P ^a   Dellamonica, P ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c Bonnet Hospital   (France)

Author keywords

Behaviour; Delayed diagnosis; HIV; HIV antibody testing; Medical care; Opportunistic infection

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRANCE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANXIETY; ATTITUDE TO HEALTH; AWARENESS; COMMUNICATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS;

EID: 22644439703     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00282.x     Document Type: Article

References (34)

1. Center for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1992; 41: 1-10.
2. Yeni P, Hammer S, Carpenter C et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2002; 288: 222-235.
3. Kirk O, Reiss P, Uberti-Foppa C et al. for seven European HIV cohorts. Safe interruption of maintenance therapy against prior infection with four common HIV-associated opportunistic pathogens during antiretroviral therapy. Ann Intern Med 2002; 13: 239-250.
4. Ledergerber BA, Mocroft P, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumoniae in HIV-1 infected individuals treated with potent antiretroviral therapy: result from eight European cohorts. N Engl J Med 2001; 3: 168-175.
5. Mocroft A, Katlama C, Johnson AM et al. for the Eurosida Study Group. The changing spectrum of AIDS across Europe: 1994-98. Results from the EuroSIDA study. Lancet 2000; 356: 291-296.
6. Mocroft A, Ledergerber B, Katlama C et al. for the Eurosida Study Group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
7. Paul S, Gilbert H, Ziecheck W, Jacobs J, Sepkowitz K. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415-418.
8. Samet J, Freedberg K, Stein M et al. Trillion virion delay: time from testing for HIV to presentation for primary care. Arch Intern Med 1998; 158: 734-740.
9. Pradier C, Pesce A, Taillan B, Roger PM, Bentz L, Dellamonica P. Reducing the incidence of Pneumocystis carinii pneumonia: a persisting challenge. AIDS 1997; 11: 833-833.
10. Edge M, Rimland D. Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia. AIDS 1999; 13: 991-992.
11. Klein M, Lalonde R. The continued occurrence of primary Pneumocystis carinii pneumonia despite the availability of prophylaxis. Clin Infect Dis 1997; 24: 522-523.
12. Moorman A, Von Bargen J, Palella F, Holmberg S and the HOPS Investigators. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. J Acquir Immune Defic Syndr 1998; 19: 182-188.
13. Bossi P, Caumes E, Astagneau P. Epidemiologic characteristics of cerebral toxoplasmosis in 339 HIV-infected patients followed between 1983 and 1994. Revue Médecine Interne 1998; 19: 313-317.
14. Gallant J, Mcavinue S, Moore R. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest 1996; 109: 586-587.
15. Schwarcz S, Katz M, Hirozawa A, Gurley J, Lemp G. Prevention of Pneumocystis carinii pneumonia: who are we missing? AIDS 1997; 11: 1263-1268.
16. Couturier E, Schwoebel V, Michon C et al. Determinants of delayed diagnosis of HIV infection in France, 1993-95. AIDS 1998; 12: 795-800.
17. Porter K, Wall P, Evans B. Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. Br Med J 1993; 307: 20-23.
18. Public Health National Network. AIDS survey in France. Bull Epidémiologique Hebdomadaire 2002; 27: 133-138.
19. Rotily M, Bentz L, Pradier C, Obadia Y, Cavallier P. Factors related to delayed diagnosis of HIV infection in southeastern France. Int J STD AIDS 2000; 11: 531-535.
20. Fennema J, Van Ameijden E, Coutinho R, Van Doornum G, Cairo I, Van Den Hoek A. HIV surveillance among sexually transmitted diseases clinic attenders in Amsterdam, 1991-96. AIDS 1998; 12: 931-938.
21. Hu D, Byers R, Fleming PI, Ward JW. Characteristics of persons with late AIDS diagnosis in the United States. Am J Prevent Med 1995; 11: 114-111.
22. Kellerman S, Lehman J, Lansky A et al. HIV testing within at-risk populations in the United States and the reasons for seeking or avoiding HIV testing. J Acquir Immune Defic Syndr 2002; 31: 202-210.
23. Jones J, Hutto P, Meyer P, Dowda H, Gamble W, Gunn RA. HIV seroprevalence and reasons for refusing and accepting HIV testing. Sex Trans Dis 1993; 20: 334-337.
24. Fylkesnes K, Rosensvard C, Kwapa P. HIV counseling and testing: overemphasizing high acceptance rates a threat to confidentiality and the right not to know. AIDS 1999; 13: 2469-2474.
25. Simon P, Weber M, Ford W, Cheng F, Kerndt P. Reasons for HIV antibody test refusal in a heterosexual sexually transmitted disease clinic population. AIDS 1996; 10: 1549-1553.
26. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP and the Aproco Cohort Study Group. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Social Sci Med 2002; 54: 1481-1496.
27. Bozzette S, Berry Sh, Duan N et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998; 339: 1897-1904.
28. Shapiro M, Morton S, McCaughey D. Variation in the care of HIV-infected adults in the United States: results of the HIV Cost and Services Utilization Study. J Am Med Assoc 1999; 281: 2305-2315.
29. Malafronte B, Perbost I, Dunais B et al. Impact of HIV infection announcing on regularity of medical follow-up. 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, October 1999 [Poster 854].
30. Obadia Y, Marimoutou C, Bouhnik A et al. Enquête sur la Situation Sociale des Personnes Vivant avec le VIH/SIDA et les Réponses Apportées par le Système de Soins et les Services Sociaux. Rapport de l'Observatoire Régional de la Santé Provence côte d'Azur. France, 1999.
31. Valdiserri R, Holtgrave D, West G. Promoting early HIV diagnosis and entry to care. AIDS 1999; 13: 2317-2330.
32. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp Mand the Swiss HIV Cohort Study. Why is HAART prescribed or discontinued? J Acquir Immune Defic Syndr 1999; 21: 114-119.
33. Jeffe DB, Meredith K, Mundy L et al. Factors associated with HIV infected patient's recognition and use of HIV medications. J Acquir Immune Defic Syndr 1998; 4: 350-360.
34. Monforte A, Cozzi Lepri A, Rezza G. Insights to the reasons for discontinuation of the first HAART regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14: 499-507.